Abstract：
Antimicrobial resistance (AMR) is a global problem that also includes countries of the Arabian Peninsula. Of particular concern, is the continuing development of extended-spectrum β-lactamases (ESBLs) in the countries of this region. Additionally, antibiotic treatment options for ESBL-producing bacteria are becoming limited, primarily due to the continuing development of carbapenem resistance (CR), carbapenems being frequently used to treat such infections. An overview of recent publications (2018-2021) indicates the presence of ESBL and/or CR in patients and hospitals in most countries of the Arabian Peninsula, although the delay between microbial isolation and publication inevitably makes an accurate analysis of the current situation rather difficult. However, there appears to be greater emphasis on CR (including combined ESBL and CR) in recent publications. Furthermore, although publications from Saudi Arabia are the most prevalent, this may simply reflect the increased interest in ESBL and CR within the country. Enhanced ESBL/CR surveillance is recommended for all countries in the Arabian Peninsula.
摘要：
抗菌素耐药性（AMR）是一个全球性问题，也包括阿拉伯半岛国家。特别令人关注的是，是该地区各国超广谱β-内酰胺酶（ESBLs）的持续发展。此外,产ESBL细菌的抗生素治疗方案变得有限，主要是由于碳青霉烯耐药性（CR）的持续发展，碳青霉烯类经常用于治疗此类感染。最近的出版物（2018-2021）的概述表明，在阿拉伯半岛的大多数国家的患者和医院中存在ESBL和/或CR，尽管微生物分离和出版之间的延迟不可避免地使得对当前情况的准确分析相当困难。然而,最近的出版物似乎更加强调CR(包括ESBL和CR的合并)。此外，尽管沙特阿拉伯的出版物最普遍，这可能只是反映了国内对ESBL和CR的兴趣增加。建议阿拉伯半岛所有国家加强ESBL/CR监测。
